N/A
Completed N=28
A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia
Source: ClinicalTrials.gov NCT01232790 ↗Enrolled (actual)
28
Serious AEs
0.0%
Results posted
Apr 2014
Primary outcomePrimary: BACS Composite RAW Score — 229.04; 227.83 units on a scale
Summary
The purpose of this study is to evaluate the effects of the amino acid supplement N-Acetylcysteine versus placebo on working memory and other cognitive functions in persons with a diagnosis of schizophrenia.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY BACS Composite RAW Score |
238.55; 239.33 | — |
| SECONDARY Letter/Number Sequencing Task Tests for Attention, Concentration & Mental Control (LNS) RAW SCORE. |
14.27; 14.44 | — |
| SECONDARY Brief Visuospatial Memory Test (BVMT) RAW SCORE. |
18.82; 17.44 | — |
| SECONDARY Brief Psychiatric Rating Scale (BPRS)Total Score |
1.70; 0.89 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects will be between 18-60
- Meet Diagnostic and Statistical Manual-IV (DSM) criteria for schizophrenia
- Be on a stable dose of antipsychotic medication for at least 1 month
- Be deemed clinically stable for 3 months by the regular clinical staff
Exclusion Criteria
- Current substance or alcohol abuse
- Pregnancy
- Clozapine treatment
- Known sensitivity to sulphur containing compounds
- Previous diagnosis of mental retardation
- Nitroglycerin use
- Asthma diagnosis, verified and treated by a primary care doctor
- Use of any other medication that may interact with the study medication
Data sourced from ClinicalTrials.gov (NCT01232790). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.